In Vitro and In Vivo Studies of the Trypanocidal Effect of Novel Quinolines.

ABSTRACT: Therapies for human African trypanosomiasis and Chagas disease, caused by Trypanosoma brucei and Trypanosoma cruzi, respectively, are limited, providing minimal therapeutic options for the millions of individuals living in very poor communities. Here the effects of 10 novel quinolines are evaluated in silico and by phenotypic studies using in vitro and in vivo models. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties revealed that most molecules did not infringe on Lipinski's rules, which is a prediction of good oral absorption. These quinolines showed high probabilities of Caco2 permeability and human intestinal absorption and low probabilities of mutagenicity and of hERG1 inhibition. In vitro screens against bloodstream forms of T. cruzi demonstrated that all quinolines were more active than the reference drug (benznidazole [Bz]), except for DB2171 and DB2192, with five (DB2187, DB2131, DB2186, DB2191, and DB2217) displaying 50% effective concentrations (EC50s) of <3 ?M (4-fold lower than that of Bz). Nine quinolines were more effective than Bz (2.7 ?M) against amastigotes, showing EC50s ranging from 0.6 to 0.1 ?M. All quinolines were also highly active in vitro against African trypanosomes, showing EC50s of ?0.25 ?M. The most potent and highly selective candidates for each parasite species were tested in in vivo models. Results for DB2186 were promising in mice with T. cruzi and T. brucei infections, reaching a 70% reduction of the parasitemia load for T. cruzi, and it cured 2 out of 4 mice infected with T. brucei DB2217 was also active in vivo and cured all 4 mice (100% cure rate) with T. brucei infection.

SUBMITTER: Nefertiti ASG 

PROVIDER: S-EPMC5786769 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature